Table 1.
Patient demographics
| Characteristic | All patients n=62 n (%) |
MBM n=40 n (%) |
SBM n=22 n (%) |
|---|---|---|---|
| Age (years) | |||
| <54 | 29 (46.8) | 18 (45.0) | 11 (55.0) |
| ≥54 | 33 (53.2) | 22 (55.0) | 11 (55.0) |
| Sex | |||
| Male | 47 (75.8) | 32 (82.5) | 14 (63.6) |
| Female | 15 (24.2) | 8 (17.5) | 8 (36.4) |
| Histology | |||
| Adenocarcinoma | 49 (79.0) | 32 (80.0) | 17 (77.3) |
| Squamous cell carcinoma | 9 (14.5) | 6 (15.0) | 3 (13.6) |
| Others | 4 (6.5) | 2 (5.0) | 2 (9.1) |
| NSCLC stage | |||
| I | 15 (24.2) | 13 (32.5) | 2 (9.1) |
| II | 19 (30.6) | 13 (32.5) | 6 (27.3) |
| III | 28 (45.2) | 14 (35.0) | 14 (63.6) |
| Number of brain metastases | |||
| 1 | 49 (79.0) | 32 (80.0) | 17 (77.3) |
| ≥2 | 13 (21.0) | 8 (20.0) | 5 (22.7) |
| RPA | |||
| I | 34 (54.8) | 24 (60.0) | 10 (45.5) |
| II | 20 (32.3) | 11 (27.5) | 9 (40.9) |
| III | 8 (12.9) | 5 (12.5) | 3 (13.6) |
Abbreviations: MBM, metachronous brain metastases; NSCLC, non–small-cell lung cancer; RPA, recursive partitioning analysis; SBM, synchronous brain metastases.